Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

• Lowell E. Schnipper, Nancy E. Davidson, +22 authors American Society of Clinical Oncology
• Journal of clinical oncology : official journal…
• 2015

Lowell E. Schnipper, Nancy E. Davidson, Dana S. Wollins, Courtney Tyne, Douglas W. Blayney, Diane Blum, Adam P. Dicker, Patricia A. Ganz, J. Russell Hoverman, Robert Langdon, Gary H. Lyman, Neal J.… (More)

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

• Amylou C Dueck, Tito R Mendoza, +22 authors Ethan M. Basch
• JAMA oncology
• 2015

IMPORTANCE To integrate the patient perspective into adverse event reporting, the National Cancer Institute developed a patient-reported outcomes version of the Common Terminology Criteria for… (More)

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

• Lowell E. Schnipper, Nancy E. Davidson, +20 authors Richard L. Schilsky
• Journal of clinical oncology : official journal…
• 2016

The mission of American Society of Clinical Oncology (ASCO) is to conquer cancer through research, education, and promotion of the highest quality patient care. Toward fulfillment of this goal and at… (More)

Evolving role of neoadjuvant therapy in rectal cancer.

• Deborah Schrag
• Current treatment options in oncology
• 2013

OPINION STATEMENT Management of locally advanced rectal cancer is complex because curative treatment routinely involves administration of surgery, chemotherapy, and radiation. Optimal treatment… (More)

Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of…

• Antonia Vickery Bennett, Amylou C Dueck, +12 authors Ethan M. Basch
• Health and quality of life outcomes
• 2016

BACKGROUND PRO-CTCAE is a library of items that measure cancer treatment-related symptomatic adverse events (NCI Contracts: HHSN261201000043C and HHSN 261201000063C). The objective of this study is… (More)

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.

• Ethan M. Basch, Allison M Deal, +4 authors Deborah Schrag
• JAMA
• 2017

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment Symptoms are common among patients receiving treatment for advanced… (More)

Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.

• Brian Wolpin, Douglas Adam Rubinson, +13 authors Alec C. Kimmelman
• The oncologist
• 2014

BACKGROUND Autophagy is a catabolic pathway that permits cells to recycle intracellular macromolecules, and its inhibition reduces pancreatic cancer growth in model systems. We evaluated… (More)

Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer

• Andrea C Enzinger, Baohui Zhang, Deborah Schrag, Holly Gwen Prigerson
• Journal of clinical oncology : official journal…
• 2015

PURPOSE To determine how prognostic conversations influence perceptions of life expectancy (LE), distress, and the patient-physician relationship among patients with advanced cancer. PATIENTS AND… (More)

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

• Alan Paul Venook, Donna Niedzwiecki, +20 authors Charles David Blanke
• JAMA
• 2017

Importance Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice… (More)

Patient-oncologist cost communication, financial distress, and medication adherence.

• Christine M Bestvina, Leah L. Zullig, +10 authors S Yousuf Zafar
• Journal of oncology practice
• 2014

BACKGROUND Little is known about the association between patient-oncologist discussion of cancer treatment out-of-pocket (OOP) cost and medication adherence, a critical component of quality cancer… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›